Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
Swansea University
Procurement - Finance, Swansea University, Singleton Park
Swansea
SA2 8PP
UK
Telephone: +44 1792295890
E-mail: procurement@swansea.ac.uk
NUTS: UKL18
Internet address(es)
Main address: www.swansea.ac.uk
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0345
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Education
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)
Reference number: SU135(20)
II.1.2) Main CPV code
38510000
II.1.3) Type of contract
Supplies
II.1.4) Short description
The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
66114000
II.2.3) Place of performance
NUTS code:
UKL18
Main site or place of performance:
Swansea University Medical School - Singleton Campus
II.2.4) Description of the procurement
he Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
II.2.5) Award criteria
Price
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2020/S 031-073690
Section V: Award of contract
Contract No: SU135(20)
A contract/lot is awarded:
No
V.1 Information on non-award
The contract/lot is not awarded
Other reasons (discontinuation of procedure)
Section VI: Complementary information
VI.3) Additional information
The funding for this equipment is on the basis of an Operating Lease for the duration of the project
(WA Ref:108879)
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.5) Date of dispatch of this notice
08/03/2021